Murat Kurtuncu

Istanbul, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 120 publications

Corrigendum to "Prevalence and incidence of neuromyelitis optica spectrum disorder in Türkiye: A nationwide epidemiologic study" [Multiple Sclerosis and Related Disorders, Volume 97 (2025): 106383].

Corrigendum to "Prevalence and incidence of neuromyelitis optica spectrum disorder in Türkiye: A nationwide epidemiologic study" [Multiple Sclerosis and Related Disorders, Volume 97 (2025): 106383].

Journal: Multiple sclerosis and related disorders

Published: September 07, 2026

How are interleukin-6 receptor antagonists shaping the future of neuromyelitis optica spectrum disorder?

How are interleukin-6 receptor antagonists shaping the future of neuromyelitis optica spectrum disorder?

Journal: Expert review of neurotherapeutics

Published: May 02, 2026

Neurofilament Light Chain as a Potential Serum-Based Biomarker for Monitoring Disease Activity in Neuro-Behçet's Disease.

Neurofilament Light Chain as a Potential Serum-Based Biomarker for Monitoring Disease Activity in Neuro-Behçet's Disease.

Journal: Noro psikiyatri arsivi

Published: April 08, 2026

Association of somatosensory evoked potentials with cervical spinal cord atrophy and disability progression in multiple sclerosis.

Association of somatosensory evoked potentials with cervical spinal cord atrophy and disability progression in multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: March 19, 2026

Clinical Use of Interleukin-6 Blockade in Neuroimmunological Disorders.

Clinical Use of Interleukin-6 Blockade in Neuroimmunological Disorders.

Journal: Noro psikiyatri arsivi

Published: February 09, 2026

Experiences of people with multiple sclerosis using clean ıntermittent catheterization: a qualitative study.

Experiences of people with multiple sclerosis using clean ıntermittent catheterization: a qualitative study.

Journal: Disability and rehabilitation

Published: December 13, 2025

Comorbid autoimmune diseases do not influence long-term disability progression in multiple sclerosis.

Comorbid autoimmune diseases do not influence long-term disability progression in multiple sclerosis.

Journal: Acta neurologica Belgica

Published: December 04, 2025

Aquaporin-1 Antibodies in Autoimmune Inflammatory Demyelinating Disorders with Predominant Optic Nerve & Spinal Cord Involvement.

Aquaporin-1 Antibodies in Autoimmune Inflammatory Demyelinating Disorders with Predominant Optic Nerve & Spinal Cord Involvement.

Journal: Noro psikiyatri arsivi

Published: November 28, 2025

Early determinants of long-term outcomes in multiple sclerosis.

Early determinants of long-term outcomes in multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: November 10, 2025

Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.

Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.

Journal: Journal of neurology

Published: November 04, 2025

Long-term prognostic features of pediatric-onset multiple sclerosis: A large cohort from Türkiye.

Long-term prognostic features of pediatric-onset multiple sclerosis: A large cohort from Türkiye.

Journal: Multiple sclerosis and related disorders

Published: October 15, 2025

Corrigendum to "Real-world evidence from Türkiye on cancer risk and treatment exposure in multiple sclerosis: A histopathology-verified, registry-based study" [MSARD, Vol.100, 2025,106547].

Corrigendum to "Real-world evidence from Türkiye on cancer risk and treatment exposure in multiple sclerosis: A histopathology-verified, registry-based study" [MSARD, Vol.100, 2025,106547].

Journal: Multiple sclerosis and related disorders

Published: August 12, 2025

Showing 1-12 of 120

Last Updated: 09/26/2026